132 related articles for article (PubMed ID: 9177293)
1. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
Esnouf RM; Stuart DI; De Clercq E; Schwartz E; Balzarini J
Biochem Biophys Res Commun; 1997 May; 234(2):458-64. PubMed ID: 9177293
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
Ren J; Esnouf RM; Hopkins AL; Warren J; Balzarini J; Stuart DI; Stammers DK
Biochemistry; 1998 Oct; 37(41):14394-403. PubMed ID: 9772165
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
Buckheit RW; Kinjerski TL; Fliakas-Boltz V; Russell JD; Stup TL; Pallansch LA; Brouwer WG; Dao DC; Harrison WA; Schultz RJ
Antimicrob Agents Chemother; 1995 Dec; 39(12):2718-27. PubMed ID: 8593008
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.
Gupta SP; Garg R
J Enzyme Inhib; 1996 Aug; 11(1):23-32. PubMed ID: 9204393
[TBL] [Abstract][Full Text] [Related]
6. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.
Hannongbua S; Pungpo P; Limtrakul J; Wolschann P
J Comput Aided Mol Des; 1999 Nov; 13(6):563-77. PubMed ID: 10584215
[TBL] [Abstract][Full Text] [Related]
8. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA
Biochemistry; 1995 Apr; 34(13):4346-53. PubMed ID: 7535561
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.
Fletcher RS; Arion D; Borkow G; Wainberg MA; Dmitrienko GI; Parniak MA
Biochemistry; 1995 Aug; 34(32):10106-12. PubMed ID: 7543775
[TBL] [Abstract][Full Text] [Related]
10. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
[TBL] [Abstract][Full Text] [Related]
11. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
[TBL] [Abstract][Full Text] [Related]
12. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).
Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A
Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038
[TBL] [Abstract][Full Text] [Related]
13. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
[TBL] [Abstract][Full Text] [Related]
15. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
[TBL] [Abstract][Full Text] [Related]
16. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
Barnard J; Borkow G; Parniak MA
Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis of 2-Phenylamino-4-phenoxyquinoline Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
Makarasen A; Patnin S; Vijitphan P; Reukngam N; Khlaychan P; Kuno M; Intachote P; Saimanee B; Sengsai S; Techasakul S
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056776
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
